Metformin (Met) inhibits AML stem cells (CD34+CD38-) in KG-1 cell line. Met selectively targets AML stem cells to eradicate leukemic stem cell. Combination of Met with idarubicin (Ida) kills both AML stem cells and leukemia cells (I, histogram; II, flowcytometry scatter plots).